GlaxoSmithKline (GSK) has reported a net profit of £1.17bn, or 28.5p per diluted share, for the second quarter ended 30 June 2024, a 28% decline compared to £1.62bn, or 39.7p per diluted share, for the respective period in 2023.
Its net income for the second quarter of 2024 (Q2 2024) increased by 12% compared to £1.04bn, or 25.4p per diluted share, for the first quarter of 2024 (Q1 2024).
The British drugmaker reported total sales of £7.88bn for Q2 2024, a 9.8% rise compared to £7.17bn for the same quarter in 2023, and a 7% rise compared to £7.36bn for Q1 2024.
GSK reported an operating profit of £1.64bn for Q2 2024, a 23% decline compared to £2.14bn for the respective period in the previous year.
The company reported a profit before taxation of £1.49bn for Q2 2024, a 25% decrease compared to £1.98bn for the same quarter in 2023.
GSK CEO Emma Walmsley said: “GSK’s momentum this year continues with excellent second quarter performance, reflecting strong operational execution and the strengthening breadth of our portfolio to both prevent and treat disease.
“Q2 sales grew in all areas, with speciality medicine in particular benefitting from new product launches in oncology and HIV. In R&D, so far this year, we have secured approvals or filings for 10 major opportunities and reported positive data from 7 phase III trials.
“We have also strengthened capabilities in key technology platforms and completed investments to develop new mRNA vaccines, ultra-long-acting HIV medicines and a promising new medicine for severe asthma.”
GSK reported a net profit of £2.21bn, or 53.9p per diluted share, for the six months ended 30 June 2024, a 28% decline compared to £3.11bn, or 76.2p per diluted share, for the same period in 2023.
The pharmaceutical company reported total sales of £15.24bn for the first half of 2024, an 8% rise compared to £14.13bn for the respective period in the previous year.
The British drugmaker reported an operating profit of £3.13bn for H1 2024, a 25% decline compared to £4.22bn for the same period in 2023.
GSK has reported a profit before tax of £2.85bn for H1 2024, a 27% decline compared to £3.9bn for the respective period in the previous year.
Recently, GSK and Flagship Pioneering, a US-based life sciences venture capital company, have signed a medicines and vaccines discovery deal worth up to $720m.
